Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.29%||79.74||0.9%||$563.79m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.06%||126.75||2.0%||$276.96m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.50%||343.30||2.7%||$275.56m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.97%||175.66||1.9%||$265.02m|
|A||Agilent Technologies, Inc.||-0.43%||69.88||1.5%||$176.42m|
|EXAS||Exact Sciences Corporation||0.92%||52.57||25.7%||$143.36m|
|SRPT||Sarepta Therapeutics, Inc.||-0.37%||80.92||16.7%||$123.27m|
|BLUE||Bluebird Bio, Inc.||-6.92%||199.80||15.8%||$122.80m|
|BMRN||BioMarin Pharmaceutical Inc.||0.63%||84.10||4.4%||$104.37m|
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.